Metastatic prostate cancer: hormone-refractory disease
{"Image DocumentName": "Metastatic prostate cancer: hormone-refractory disease", "Image ImageDescription": "When men with prostate cancer develop biochemical evidence of hormone-refractory disease, their treatment options should be discussed by the urological cancer multidisciplinary team with a view to seeking an oncologist and/or specialist palliative care opinion, as appropriate. NOTES FOR PRESENTERS: Key points to raise: The NICE guideline includes recommendations on hormonal therapy, managing the complications of hormonal therapy, hormone-refractory prostate cancer and palliative care. More information on the pharmacological treatment of hormone-refractory prostate cancer (for example the use of docetaxel and corticosteroids) and recommendations on imaging are given in sections \u2212 of the NICE guideline. Recommendations , and identify treatments which are NOT recommended. Key recommendation in full: as shown on this slide [1.7.10, NICE guideline] Additional information: Docetaxel is recommended, within its licensed indications, as a treatment option for men with hormone-refractory prostate cancer only if their Karnofsky performance-status score is 60% or more [1.7.11, NICE guideline]. It is recommended that treatment with docetaxel should be stopped: at the completion of planned treatment of up to 10 cycles, or if severe adverse events occur, or in the presence of progression of disease as evidenced by clinical or laboratory criteria, or by imaging studies [1.7.12, NICE guideline]. Repeat cycles of treatment with docetaxel are not recommended if the disease recurs after completion of the planned course of chemotherapy [1.7.13, NICE guideline]. NOTE: These recommendations are from \u2018Docetaxel for the treatment of hormone-refractory metastatic prostate cancer\u2019 (NICE technology appraisal guidance 101).", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}